Merilog, classified as a rapid-acting human insulin analog, is designed to reduce mealtime blood sugar spikes, improving blood sugar management for adults and pediatric diabetes patients.

TI has a more rapid onset of action than rapid-acting insulin analogs. In this study, adults with type 1 diabetes initiated a regimen of TI plus insulin degludec after completing the usual-care ...

In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering, allowing users to mimic physiological insulin secretion to avoid hypoglycaemia ...

Click here to read the article now. TI has a more rapid onset of action than rapid-acting insulin analogues. In this study, adults with type 1 diabetes initiated a regimen of TI plus insulin ...

studies conducted with non-commercially available analog formulations, or trials conducted with insulin preparations that are no longer commercially available.

a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Va. Civica will commercialize the medicine for patients in the United States, after completion of development work and ...

It is the first biosimilar of a rapid-acting insulin product – used to control the blood glucose spike after meals – and only the third insulin biosimilar to be approved in the US. Novo ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...